Which has higher valuation and earnings, IFRX or RNXT?

RenovoRx has higher revenue and earnings than InflaRx. RenovoRx is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $29.33K 3,992.86 -$51.63M -$0.71 N/A RenovoRx $1.12M 34.26 -$11.17M -$0.33 N/A

Is IFRX or RNXT more profitable?

InflaRx has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. InflaRx's return on equity of -88.30% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% RenovoRx -823.98% -135.03% -101.92%

Does the media prefer IFRX or RNXT?

In the previous week, RenovoRx had 8 more articles in the media than InflaRx. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat RenovoRx's score of -0.51 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend SPRO or RNXT?

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 899.18%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is SPRO or RNXT more profitable?

Spero Therapeutics has a net margin of 24.90% compared to RenovoRx's net margin of -823.98%. Spero Therapeutics' return on equity of 35.58% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Spero Therapeutics 24.90% 35.58% 24.95% RenovoRx -823.98% -135.03% -101.92%

Does the media refer more to SPRO or RNXT?

In the previous week, RenovoRx had 8 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.89 beat RenovoRx's score of -0.51 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer PLX or RNXT?

In the previous week, RenovoRx had 9 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 10 mentions for RenovoRx and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 beat RenovoRx's score of -0.51 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer RNXT or ORMP?

RenovoRx presently has a consensus target price of $8.50, suggesting a potential upside of 899.18%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts plainly believe RenovoRx is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor RNXT or ORMP?

In the previous week, RenovoRx had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 10 mentions for RenovoRx and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat RenovoRx's score of -0.51 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

RenovoRx (RNXT) Competitors

$0.85 -0.01 (-1.08%)

Closing price 06/10/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.01 (+0.86%)

As of 04:28 AM Eastern

Compare

RNXT vs. IFRX, SPRO, PLX, MOLN, and ORMP

Should you buy RenovoRx stock or one of its competitors? MarketBeat compares RenovoRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RenovoRx include InflaRx (IFRX), Spero Therapeutics (SPRO), Protalix BioTherapeutics (PLX), Molecular Partners (MOLN), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.

How does RenovoRx compare to InflaRx?

InflaRx (NASDAQ:IFRX) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

InflaRx currently has a consensus target price of $7.00, suggesting a potential upside of 332.10%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 899.18%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

42.4% of InflaRx shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 9.1% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InflaRx has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. InflaRx's return on equity of -88.30% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
RenovoRx	-823.98%	-135.03%	-101.92%

InflaRx has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

RenovoRx has higher revenue and earnings than InflaRx. RenovoRx is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$29.33K	3,992.86	-$51.63M	-$0.71	N/A
RenovoRx	$1.12M	34.26	-$11.17M	-$0.33	N/A

In the previous week, RenovoRx had 8 more articles in the media than InflaRx. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.79 beat RenovoRx's score of -0.51 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

InflaRx beats RenovoRx on 10 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Spero Therapeutics has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$54.77M	2.69	$8.57M	$0.24	10.58
RenovoRx	$1.12M	34.26	-$11.17M	-$0.33	N/A

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 899.18%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 8 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.89 beat RenovoRx's score of -0.51 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 9.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to RenovoRx's net margin of -823.98%. Spero Therapeutics' return on equity of 35.58% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
RenovoRx	-823.98%	-135.03%	-101.92%

Spero Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Summary

Spero Therapeutics beats RenovoRx on 10 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 509.14%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 899.18%. Given RenovoRx's higher possible upside, analysts plainly believe RenovoRx is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Protalix BioTherapeutics has a net margin of -21.03% compared to RenovoRx's net margin of -823.98%. Protalix BioTherapeutics' return on equity of -30.89% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
RenovoRx	-823.98%	-135.03%	-101.92%

Protalix BioTherapeutics has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.08	$8.31M	$0.18	10.94
RenovoRx	$1.12M	34.26	-$11.17M	-$0.33	N/A

In the previous week, RenovoRx had 9 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 10 mentions for RenovoRx and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 beat RenovoRx's score of -0.51 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Protalix BioTherapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 9.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Protalix BioTherapeutics beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Molecular Partners?

RenovoRx (NASDAQ:RNXT) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

RenovoRx has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

In the previous week, RenovoRx had 8 more articles in the media than Molecular Partners. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.44 beat RenovoRx's score of -0.51 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
RenovoRx	Negative
Molecular Partners	Neutral

RenovoRx has higher earnings, but lower revenue than Molecular Partners. RenovoRx is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	34.26	-$11.17M	-$0.33	N/A
Molecular Partners	$5.65M	28.02	-$74.41M	-$1.94	N/A

RenovoRx presently has a consensus target price of $8.50, suggesting a potential upside of 899.18%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 113.65%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Molecular Partners has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Molecular Partners' return on equity of -66.62% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Molecular Partners	N/A	-66.62%	-54.85%

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

RenovoRx and Molecular Partners tied by winning 8 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Oramed Pharmaceuticals?

RenovoRx (NASDAQ:RNXT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

RenovoRx has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Oramed Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Oramed Pharmaceuticals' return on equity of -5.37% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, RenovoRx had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 10 mentions for RenovoRx and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat RenovoRx's score of -0.51 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RenovoRx presently has a consensus target price of $8.50, suggesting a potential upside of 899.18%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts plainly believe RenovoRx is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	34.26	-$11.17M	-$0.33	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.43

Summary

Oramed Pharmaceuticals beats RenovoRx on 10 of the 16 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.78M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.32%	2.67%	5.61%
P/E Ratio	-2.58	18.83	24.41	23.63
Price / Sales	34.26	294.45	502.47	103.82
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	5.67	8.00	10.35	6.70
Net Income	-$11.17M	$23.89M	$3.56B	$337.26M
7 Day Performance	-12.78%	-5.43%	-3.02%	-2.46%
1 Month Performance	0.08%	-4.18%	-0.41%	0.31%
1 Year Performance	-37.45%	36.70%	20.04%	23.15%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	3.5234 of 5 stars	$0.85 -1.1%	$8.50 +899.2%	-36.5%	$38.78M	$1.12M	N/A	6	Analyst Upgrade Gap Up
IFRX InflaRx	2.8688 of 5 stars	$2.17 -4.8%	$7.00 +222.6%	+92.9%	$164.83M	$30K	N/A	60	News Coverage Positive News Gap Down
SPRO Spero Therapeutics	1.8716 of 5 stars	$2.83 flat	N/A	-10.9%	$163.86M	$66.80M	11.79	150	News Coverage Positive News
PLX Protalix BioTherapeutics	2.5043 of 5 stars	$2.00 -3.2%	$12.00 +501.5%	+24.7%	$160.74M	$76.38M	N/A	200
MOLN Molecular Partners	2.4497 of 5 stars	$3.92 -0.8%	$8.38 +113.6%	+3.3%	$159.48M	$5.65M	N/A	180	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. IFRX, SPRO, PLX, MOLN, and ORMP

How does RenovoRx compare to InflaRx?

Summary

How does RenovoRx compare to Spero Therapeutics?

Summary

How does RenovoRx compare to Protalix BioTherapeutics?

Summary

How does RenovoRx compare to Molecular Partners?

Summary

How does RenovoRx compare to Oramed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. IFRX, SPRO, PLX, MOLN, and ORMP

How does RenovoRx compare to InflaRx?

Do analysts prefer IFRX or RNXT?

Do insiders & institutionals hold more shares of IFRX or RNXT?

Is IFRX or RNXT more profitable?

Which has more volatility & risk, IFRX or RNXT?

Which has higher valuation and earnings, IFRX or RNXT?

Does the media prefer IFRX or RNXT?

Summary

How does RenovoRx compare to Spero Therapeutics?

Which has stronger earnings and valuation, SPRO or RNXT?

Do analysts recommend SPRO or RNXT?

Does the media refer more to SPRO or RNXT?

Do insiders & institutionals have more ownership in SPRO or RNXT?

Is SPRO or RNXT more profitable?

Which has more volatility and risk, SPRO or RNXT?

Summary

How does RenovoRx compare to Protalix BioTherapeutics?

Do analysts recommend PLX or RNXT?

Is PLX or RNXT more profitable?

Which has stronger earnings & valuation, PLX or RNXT?

Does the media prefer PLX or RNXT?

Which has more volatility and risk, PLX or RNXT?

Do institutionals and insiders hold more shares of PLX or RNXT?

Summary

How does RenovoRx compare to Molecular Partners?

Which has more volatility & risk, RNXT or MOLN?

Does the media favor RNXT or MOLN?

Which has better earnings & valuation, RNXT or MOLN?

Do analysts prefer RNXT or MOLN?

Is RNXT or MOLN more profitable?

Do insiders & institutionals believe in RNXT or MOLN?

Summary

How does RenovoRx compare to Oramed Pharmaceuticals?

Which has more volatility and risk, RNXT or ORMP?

Is RNXT or ORMP more profitable?

Do insiders and institutionals have more ownership in RNXT or ORMP?

Does the media favor RNXT or ORMP?

Do analysts prefer RNXT or ORMP?

Which has higher earnings & valuation, RNXT or ORMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools